Virus Discovery Among Bats in China Fruit Orchards Draw Exposure Concerns
The discovery was made by a team of scientists led by Guopeng Kuang from the Yunnan Institute of Endemic Disease Control and Prevention and Tian Yang from Dali University in China, who used genetic analysis to identify microbes in 142 bats from 10 different species. They found 20 new viruses in total, along with a new bacterium and a new protozoan parasite.
The viruses of concern are both henipaviruses, which are known for their long genomes and wide range of hosts. More than half of the new viruses' genes match those of the Nipah and Hendra viruses, which, while highly lethal to humans who are infected, are relatively rare among our species.
It's unclear whether these two new henipaviruses have the genetic machinery to cross from bats to other species, but their similarity to known human pathogens means scientists will be keeping a close eye on them.
"These viruses are particularly concerning because they were predominantly found in bat kidneys, a site linked to urine production, raising alarm about potential human exposure via contaminated fruits or water (routes implicated in previous outbreaks)," says molecular virologist Vinod Balasubramaniam from Monash University in Malaysia, who was not involved in the study.
That the bats were captured in fruit orchards means that if the viruses were capable of jumping between species, humans and domestic animals would make easy targets.
Related:
But bats are also an important asset to orchards: they can pollinate fruits, fertilize soil, and prey on insects. For instance, 90 percent of bats in China that are insectivorous save the country's apple farmers an estimated US$2 billion in crop losses each year.
As University of Sydney veterinarian and wildlife disease ecologist Alison Peel, who was also not involved in the study, points out: "We have other examples of close evolutionary cousins to Hendra and Nipah that appear not to be of any concern for spillover, so there will need to be some more laboratory studies on these new viruses to determine the actual risk."
The research is published in PLOS Pathogens.
Scientists Revealed How Much Exercise You Need to 'Offset' Sitting All Day
Social Media Might Impair Your Recovery From Injury. Here's Why.
Cat Parasite Can Seriously Disrupt Brain Function, Study Suggests
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 hours ago
- Medscape
Stapokibart Improves Rhinosinusitis With Nasal Polyps
Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from 179 individuals. Biologics are now more commonly used as treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), and monoclonal antibodies have emerged as significantly more effective than other biologics for these patients, wrote Shen Shen, MS, of Capital Medical University, Beijing, China, and colleagues. In a study known as CROWNS-2 published in JAMA , the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 mg subcutaneously) or a placebo injection every 2 weeks for 24 weeks. All participants also received 100 μg of mometasone furoate per nostril once a day as background treatment before and during the study. The co-primary endpoints were changes in nasal polyp score and nasal congestion score from baseline to 24 weeks in the study population overall and in the subgroup with eosinophilic chronic rhinosinusitis with nasal polyps. The 24-week double-blind period was followed by an open-label extension to 52 weeks. Key secondary endpoints included the percentage of patients who achieved improvement of 1 point or more on nasal polyp scores and 2 points or more on nasal polyp scores. The final analysis included 90 individuals in the stapokibart group and 89 in the placebo group. The mean age of the study population was 45 years, and approximately one third were women. The mean duration of CRSwNP was 6.0 years, and 139 patients (77.7%) had eosinophilic CRSwNP. Study Outcomes Compared with placebo patients at 24 weeks, patients in the stapokibart group had a significant reduction in polyp size, with least-squares mean (LSM) changes in nasal polyp score from baseline of -2.6 and -0.3 points, respectively ( P < .001). Similarly, patients in the stapokibart group had a significantly greater LSM change in nasal congestion score from baseline to week 24 than those in the placebo group (-1.2 points vs -0.5 points, respectively; P < .001). Nearly all of the patients treated with stapokibart (96.5%) had a reduction in nasal polyp score of at least 1 point, and 89.5% had a reduction of at least 2 points after 52 weeks. The improvements in both primary endpoints were even greater among patients with eosinophilia, with an LSM change of -3.0 vs -0.04 for nasal polyp scores and -1.3 vs -0.5 for nasal congestion scores in stapokibart vs placebo patients, respectively. The overall incidence of adverse events in the first 24 weeks of the study was similar for the stapokibart and placebo groups. The most common adverse events were upper respiratory tract infections, COVID-19, and unconfirmed but suspected COVID-19. Serious adverse events were rare and similar between the stapokibart and placebo groups (2.2% vs 1.1%). However, higher rates of arthralgia and hyperuricemia were reported with stapokibart than with placebo (7.8% vs 0% and 5.6% vs 1.1%, respectively). The findings were limited by several factors, including the lack of data on aspirin-exacerbated respiratory disease, the small numbers of patients, and the inclusion only of patients in China, the researchers noted. However, the results support the potential of stapokibart to reduce nasal polyp size and symptom severity in adults with severe CRSwNP, they concluded. Emergence of Endotyping The significant reduction in polyp score was the study's most notable finding, according to an accompanying editorial. 'The emergence of biologic therapies for chronic rhinosinusitis with nasal polyps has brought the concept of inflammatory endotyping to the forefront of this condition,' wrote Michael P. Platt, MD, of Boston University Chobanian & Avedisian School of Medicine, Boston; Stacey T. Gray, MD, of Harvard Medical School, Boston; and Anju T. Peters, MD, of Northwestern University Feinberg School of Medicine, Chicago. The current study included a majority of individuals with eosinophilic CRSwNP, and the successful reduction in polyp size was based on correct identification of this T2 endotype, as stapokibart targeted T2 inflammation, they said. However, choosing the appropriate biologic therapy for uncontrolled CRSwNP with nasal polyps also requires consideration of other comorbid atopic diseases and disease pathogenesis, with shared decision-making, they added. Tuning in to Eosinophilia 'Currently, three biologics are approved for CRSwNP in the US, with additional agents likely to follow,' said Michael S. Blaiss, MD, an allergist and clinical professor at the Medical College of Georgia at Augusta University, Augusta, Georgia, in an interview. 'What distinguishes this trial is that the investigators specifically defined and studied eosinophilic CRSwNP,' said Blaiss, who was not involved in the study. 'In this subgroup, the biologic demonstrated significant efficacy, providing important data for this population of CRSwNP sufferers,' he said. The study findings were not unexpected, as stapokibart has a similar mechanism of action to dupilumab, said Blaiss. 'Both target the IL-4Rα [interleukin-4 receptor subunit alpha] receptor, albeit at different binding sites and affinities, and dupilumab is already FDA-approved for CRSwNP, so efficacy was expected,' he said. 'However, safety findings warrant attention,' he emphasized. The significantly greater occurrence of arthralgia and hyperuricemia in stapokibart vs placebo patients deserves further evaluation in larger and longer studies, Blaiss said. 'If approved, this biologic would provide an additional treatment option for patients with moderate to severe CRSwNP,' Blaiss told Medscape Medical News . However, its advantages over currently available biologics remain unknown, as the dosing schedule of every 2 weeks does not improve convenience, he noted. 'Head-to-head comparative studies are needed, similar to the recent dupilumab vs omalizumab trial in CRSwNP, to determine whether one biologic is clinically superior,' said Blaiss. 'Furthermore, evaluation in noneosinophilic CRSwNP is necessary, as the present study included too few patients in this subgroup for meaningful statistical analysis,' he added.
Yahoo
15 hours ago
- Yahoo
Vital Materials Released Quantum Flux Photon Counting CT (PCCT) Full Vertical Integration Technology
BEIJING, Aug. 19, 2025 /PRNewswire/ -- From August 15-17, the 31st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held in Beijing. Vital Materials officially launched the VITA Genesis, China's fully proprietary Photon Counting CT (PCCT) scanner, marking the entry of global medical imaging technology into the "Quantum Flux" sensing era and empowering Chinese innovation in precision diagnostics and treatment. The Photon Counting Detectors (PCD), as the core technology of PCCT, differ significantly from traditional Energy Integrating Detectors (EID). Traditional CT scanners require X-ray photons to first be converted into visible light, then into electrical signals. In contrast, the PCCT detector employs semiconductor materials, where X-ray photons excite electrons, creating electron-hole pairs proportional to photon energy. Charge carriers from the pairs are separated by an electric field to generate electrical pulses. Application-Specific Integrated Circuits (ASIC) categorize these pulses by energy bins, enabling precise photon counting and energy resolution. This breakthrough provides crucial technical support for multi-energy spectral imaging, significantly enhancing the diagnostic value of medical imaging. Currently, the PCCT detectors primarily utilize three materials: Cadmium Zinc Telluride (CdZnTe or CZT), Cadmium Telluride (CdTe), and Deep Silicon. CZT is emerging as a breakthrough for next-generation medical imaging technology due to its outstanding detection capabilities. The core value of VITA Genesis lies not only in adopting a detector solution based on the CZT, but more importantly in pioneering the mastery of PCCT's full vertical integration technology. This includes ultra-high purity metals purification and compounding, single crystal growth and processing, component design and development, CT system integration, and imaging algorithm development, establishing a global paradigm in the field of PCCT. Contact: View original content to download multimedia: SOURCE Vital Materials
Yahoo
17 hours ago
- Yahoo
Overview of the China Optics Valley Artificial Intelligence Innovation Conference & 2025 Forbes China AI Tech Enterprises Top 50 Release Ceremony
Wuhan, China--(Newsfile Corp. - August 19, 2025) - On June 27, in the grand banquet hall on the third floor of the China Optics Valley Technology Exhibition Center, the "China Optics Valley Artificial Intelligence Innovation Conference & 2025 Forbes China AI Tech Enterprises Top 50 Release Ceremony" took place, featuring the release of the comprehensive "China's Optics Valley Report", which highlighted major developments and broad insights for the global AI industry. Aiming for "China's Fourth AI Pole" In his opening speech, Shen Yue, a member of the Standing Committee of the CPC Wuhan Municipal Committee and Secretary of the Party Working Committee of the Wuhan East Lake High-tech Development Zone, revealed the "report card" and "roadmap": Industry Scale: By 2024, the AI industry in Optics Valley was expected to exceed 45 billion yuan, with a three-year goal of reaching 100 billion yuan, nurturing three leading companies worth 10 billion yuan and a thousand SMEs. Computing Power Base: With the leading intelligent computing/supercomputing center in China, the national storage base in the country, and the largest optical communication R&D base globally, comprehensive support for AI from storage to computing is ensured. Talent and Funds: A global talent attraction plan has been launched, offering up to 100 million yuan in support for top scientists; a 10 - billion - yuan humanoid robot master fund coordinated by Hubei provincial, Wuhan municipal and East Lake High-tech Development Zone governments is set to launch. Open Scenarios: A massive autonomous driving operational zone reaching 7.7 million people and covering 3,000 square kilometers, a big data pool of 12 million cervical cancer screenings ensures abundant data and scenarios for large models. "Pooling Strengths, Driving Breakthroughs" Industry Collaboration Signing Ceremony: Multiple AI Firms Establish Presence in Optics Valley of China During the "Pooling Strengths, Driving Breakthroughs" collaboration signing ceremony, several leading companies ranked in the 2025 Forbes China AI Tech Enterprises Top 50 list signed strategic cooperation agreements with the East Lake High-Tech Development Zone. Representing core AI sectors—including autonomous driving, XR-powered cultural tourism, industrial quality inspection, healthcare robotics, AIGC content generation, and intelligent computing infrastructure—these companies span a full-stack ecosystem, from foundational large models to end-to-end application scenarios. World-Class Brainstorming: Key Insights from Four Academicians and Experts AI Paradigm Leap From healthcare to cultural tourism, from industry to daily life, the conference highlighted ten transformative breakthroughs shaping the future of AI: Trusted Interaction: Achieving high accuracy in urban hotlines, bank counters services, and autonomous driving operations, elevating AI from mere "understanding" to active "management". AI-Native Creativity: Generating 33.27 million pixel-level images from a single prompt, compressing the traditional "shoot-edit-publish" process into minutes. Medical Scenarios: Diagnostic-level large models advancing evidence-based medicine into an "intent-driven" era, validated by millions of screening data in "no doctor" scenarios. Additionally, Integrating family doctors, fall monitoring, and emergency calls into service robots, deeply engaging with rural areas and communities to address the aging population. Cultural Tourism: Ultra-high-resolution immersive experiences bringing millennia-old murals to life, enabling a 25-minute journey along the Silk Road. Embodied Intelligence: Completing training-deployment loops in 45 days via simple voice commands, achieving a new paradigm of human-AI collaboration. Content Production: AI workstations scaling to 20 million users in 20 months, transforming diverse physical environments into trainable "embodied AI" interfaces. Industrial Quality Inspection: Nano-level defect detection setting new industry benchmarks and driving a national AI initiative targeting 2030. Manufacturing Methodology: Introducing a new industrial AI framework: "scene-first + model collaboration + five core capabilities." Computing Infrastructure Consensus: A shift toward inference dominance - predicting that inference compute demand will soon surpass training, redefining the next generation of AI factories. Autonomous Driving: Achieving global deployment across over 100 projects within three days, with remote safety operators leading commercialization efforts. The ten paradigms collectively outline a future vision of "AI being everywhere, seamlessly integrated into daily life." Four Roundtables, One Message: Scenarios Are King, Collaboration Is Key Addressing the integration bottlenecks in embodied intelligence, the tripartite complementarity of technology, scenarios, and funding, and the emerging consensus around smart manufacturing - defined by "data × model × software-hardware co-design," the four roundtable discussions converged on a shared conclusion: as of 2025, AI competitiveness no longer hinges on showcasing isolated technologies, but on who can fastest embed algorithms into real-world scenarios, integrate computing power into industrial workflows, and attract capital to secure global orders. Wuhan unveiled a series of initiatives to accelerate this transformation, including： A "humanoid robot marathon testbed," to advance embodied AI; A support package for SMEs featuring "computing power vouchers," open data access, and an industry-finance collaboration platform; Making Optics Valley of China the "World Optics Valley" in the AI Era The 2025 Forbes China AI Tech Enterprises Top 50 Award Ceremony was held with great acclaim, honoring: 50 core technology pioneers, 10 breakthrough AI applications, 10 cutting-edge technologies, 10 rising startups, and 15 influential leaders shaping the future of AI. At this pivotal moment, Optics Valley not only celebrate achievement but also illuminated the path forward: "From a beam of light to a city, from a city to an era." The sparks of AI innovation have ignited a torch in Optics Valley of China. Next stop, the World Optics Valley! Media contactContact: Austin LeeCompany Name: ForbesChinaWebsite: info@ To view the source version of this press release, please visit
